Author: digi

Defining KPIs and KRIs for Contamination Control Performance Effective Definition of KPIs and KRIs for Contamination Control in Aseptic Manufacturing Contamination control remains one of the most critical aspects of pharmaceutical manufacturing, especially in aseptic processing environments. Regulatory bodies such as the FDA, EMA, MHRA, and PIC/S emphasize the importance of maintaining stringent contamination control…

Read More “Defining KPIs and KRIs for Contamination Control Performance” »

Using Data Analytics on EM and Utility Data to Spot Emerging Contamination Risks Applying Data Analytics to Environmental and Utility Data for Enhanced Contamination Control in Aseptic Manufacturing Pharmaceutical aseptic manufacturing demands rigorous control strategies to ensure product sterility and patient safety. With the revisions of Annex 1 and heightened regulatory expectations across the EU…

Read More “Using Data Analytics on EM and Utility Data to Spot Emerging Contamination Risks” »

Risk-Based Reduction of EM Points: When Is It Justified and How to Defend It? Risk-Based Reduction of Environmental Monitoring Points: A Step-by-Step GMP Guide Aligned with Annex 1 Environmental monitoring (EM) is critical for maintaining contamination control within aseptic manufacturing environments. Regulatory bodies such as the FDA, EMA, MHRA, and PIC/S mandate strict environmental monitoring…

Read More “Risk-Based Reduction of EM Points: When Is It Justified and How to Defend It?” »

Setting Up EM and CCS for New Facilities Before First GMP Production Step-by-Step Guide to Setting Up Environmental Monitoring and Contamination Control Strategy in New GMP Facilities Establishing an effective environmental monitoring (EM) and contamination control strategy (CCS) is a cornerstone of compliance and sterility assurance in aseptic manufacturing. Prior to initiating first Good Manufacturing…

Read More “Setting Up EM and CCS for New Facilities Before First GMP Production” »

Visual Management and Signage in Clean Areas to Reinforce Contamination Rules Implementing Visual Management and Signage in Clean Areas to Strengthen Contamination Control In pharmaceutical aseptic manufacturing, adherence to contamination control principles, as prescribed by Annex 1, is critical to assure sterility assurance and product quality. A key element in supporting staff compliance and maintaining…

Read More “Visual Management and Signage in Clean Areas to Reinforce Contamination Rules” »

Using Mock Scenarios to Train Staff on Contamination Control Decision-Making Enhancing Contamination Control Decision-Making through Mock Scenarios in Pharmaceutical Aseptic Manufacturing Contamination control is vital in pharmaceutical aseptic manufacturing, where maintaining sterility assurance is paramount to product quality and patient safety. Regulatory guidelines such as EU GMP Annex 1 and FDA 21 CFR Parts 210…

Read More “Using Mock Scenarios to Train Staff on Contamination Control Decision-Making” »

Integrating CCS Outcomes Into Deviation, CAPA and Change Control Step-by-Step Tutorial: Integrating CCS Outcomes Into Deviation, CAPA and Change Control in Aseptic Manufacturing In modern sterile pharmaceutical manufacturing, maintaining sterility assurance is paramount. This requires a comprehensive contamination control strategy (CCS) that aligns with regulatory expectations, particularly those outlined in Annex 1 of the EU…

Read More “Integrating CCS Outcomes Into Deviation, CAPA and Change Control” »

How to Present CCS During EU and MHRA Annex 1-Focused Inspections Effective Presentation of Contamination Control Strategy (CCS) During EU and MHRA Annex 1 Inspections Achieving compliance with the latest Annex 1 revision and accompanying contamination control expectations is a critical milestone for any pharmaceutical sterile manufacturing facility. Preparation for regulatory inspections by the European…

Read More “How to Present CCS During EU and MHRA Annex 1-Focused Inspections” »

Common Annex 1 Contamination Control Deficiencies in Recent Inspection Reports Step-by-Step Guide to Addressing Common Annex 1 Contamination Control Deficiencies Pharmaceutical aseptic manufacturing is a highly specialized area within Good Manufacturing Practice (GMP) that demands rigorous contamination control to ensure patient safety and sterility assurance. The updated Annex 1 to EU GMP sets detailed requirements…

Read More “Common Annex 1 Contamination Control Deficiencies in Recent Inspection Reports” »

Annex 1 Requirements for ATMP and Cell Therapy Aseptic Environments Step-by-Step Guide to Annex 1 Requirements for ATMP and Cell Therapy Aseptic Environments Advanced Therapy Medicinal Products (ATMPs) and Cell Therapy products represent a highly specialized segment of pharmaceutical manufacturing requiring stringent aseptic processes to ensure sterility assurance and product quality. Regulatory authorities including the…

Read More “Annex 1 Requirements for ATMP and Cell Therapy Aseptic Environments” »